The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
